Eli Lilly Industry Symposium: Part 1: Tirzepatide in OSA – What does the evidence say?
Tracks
Track 4
| Thursday, October 9, 2025 |
| 12:35 PM - 1:20 PM |
|
Sponsored By:
Eli Lilly
|
Details
Tirzepatide - What benefits for patients suffering from moderate to severe Obstructive Sleep Apnoea and Obesity.
In this session, the speakers will highlight several clinical studies on Tirzepatide to showcase the results. We will go into detail about what Tirzepatide is and its dual mechanism of action (GIP/GLP-1). We will then take a closer look at two key studies – SURMOUNT-1 and SURMOUNT-OSA. Finally, we will open the floor to the audience with a Q&A session.
Speaker
Prof Ron Grunstein
Head, Sleep & Circadian Research Group
Woolcock Institute of Medical Research
Eli Lilly Industry Symposium Part 1: Tirzepatide in OSA – What does the evidence say?
Biography
Dr Ted Wu
Eli Lilly Industry Symposium Part 1: Tirzepatide in OSA – What does the evidence say?
Biography
